Endoscopic Tympanoplasty: Single Versus Double Flap Technique
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03922295 |
|
Recruitment Status :
Completed
First Posted : April 19, 2019
Last Update Posted : September 10, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tympanic Membrane Perforation | Procedure: Endoscopic tympanoplasty | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Endoscopic Tympanoplasty: Single Versus Double Flap Technique |
| Actual Study Start Date : | August 24, 2017 |
| Actual Primary Completion Date : | February 20, 2019 |
| Actual Study Completion Date : | February 20, 2019 |
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: endoscopic double flap group |
Procedure: Endoscopic tympanoplasty
In the double flap group, graft is placed via elevation of both posterior and anterior flaps. In the single flap group, graft is placed via elevation of posterior flap only |
| Active Comparator: endoscopic single flap group |
Procedure: Endoscopic tympanoplasty
In the double flap group, graft is placed via elevation of both posterior and anterior flaps. In the single flap group, graft is placed via elevation of posterior flap only |
- Healing or graft take rate [ Time Frame: 3 months after surgery ]closure of tympanic membrane perforation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with chronic suppurative otitis media with total or subtotal tympanic membrane perforation with limited anterior remnant.
- dry perforation for at least 3 months.
Exclusion Criteria:
- Recurrent perforation after previous myringoplasty.
- Ossicular disruption or fixation.
- immune-compromised patients including uncontrolled diabetics, chronic liver and kidney diseases.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03922295
| Egypt | |
| ORL-HNS department,Mansoura University Hospital, Faculty of Medicine, Mansoura University | |
| Mansoura, ElDakahlia, Egypt, 35516 | |
| Principal Investigator: | Noha A Elkholy | ORL-HNS department, Faculty of Medicine, Mansoura University | |
| Study Director: | Mohammed A Salem | ORL-HNS department, Faculty of Medicine, Mansoura University | |
| Study Chair: | Abdelwahab M Rakha | ORL-HNS department, Faculty of Medicine, Mansoura University |
Documents provided by Noha A.Elkholy, Mansoura University:
| Responsible Party: | Noha A.Elkholy, ORL-HNS Resident, Mansoura University |
| ClinicalTrials.gov Identifier: | NCT03922295 |
| Other Study ID Numbers: |
1ORL |
| First Posted: | April 19, 2019 Key Record Dates |
| Last Update Posted: | September 10, 2019 |
| Last Verified: | September 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Tympanic Membrane Perforation Ear Diseases Otorhinolaryngologic Diseases Wounds and Injuries |

